Liste des publications sur PubMed

Depuis 2008:

Bouhamdani N, Comeau D, and Turcotte S. Targeting lysosome function causes selective cytotoxicity in VHL-deficient renal cell carcinomas. Carcinogenesis 2019, Sep26 (Epub ahead of print) IF: 4.64

Selka A, Doiron JA, Lyons P, Dastous S, Chiasson A, Turcotte S, Surette ME, and Touaibia M. Discovery of novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induced apoptosis in RCC4 renal cancer cells. Eu. J. Med. Chem, 179, 347-357, 2019 IF: 5.14

Bouhamdani N, Comeau D, and Turcotte S. STF-62247 accumulates in lysosome and blocks late-stage of autophagic to sensitize VHL-mutated cells. Am J Physiol Cell Physiol. 316(5), C605-C620, 2019 IF: 3.54

Bouhamdani N, Joy A, Barnett D, Cormier K, Léger D, Chute I, Ouellette RJ, Lamarre S and Turcotte S*. Quantitative proteomics to identify signaling of a small molecule that target the loss of VHL in Renal Cell Carcinoma, Int. J. Cancer141 (4), 778-790, 2017 IF: 7.4

Cuperlovic-Culf M, Cormier K, Touaibia M, Reyjal J, Robichaud S, Belbraouet M and Turcotte S. 1H NMR Metabolomics analysis of renal cell carcinoma cells: VHL and HIF effects on metabolism. Int. J. Cancer 138(10), 2439-2449, 2016 IF:7.4

Cormier K, Curry RD, Betsch MP, Goguen JA, Vogels CH, Decken A, Turcotte S and Westcott SA. Synthesis, characterization, and anticancer activities of pyrogallol-based arylspiroborates. J. of Heterocyclic Chem, Epub print 27 july 2015 IF: 1.14

Jean S, Cormier K, Patterson AE, Vogels CM, Decken A, Robichaud G, Turcotte S and Westcott SA. Synthesis, characterization and anticancer properties of organometallic Schiff base platinum complexes. Can J. of Chem 93(10), 1140-1146, 2015 IF:1.1

Reyjal J, Cormier and Turcotte S. Autophagy and programmed cell death to target cancer cells : exploiting synthetic lethality as cancer therapeutic. Adv. Exp. Biol. 772, 167-188, 2014 IF:1.8

Reaume N, Graham GE, Tomiak E, Kamel-Reid S, Jewett MAS, Bjarnason G, Blais N, Care M, Drachenberg D, Gedye C, Grant R, Heng D, Kollmannsberger C, Lattouf JB, Pause A, Reuther D, Soulieres D, Tanguay S, Turcotte S, Violette P, Wood L, Basiuk J and Pautler SE, Canadian Guideline on Genetic Screening for Hereditary Renal Cell Carcinoma. Can Urol Assoc J. 9-10, 319-323, 2013. IF: 1.8

Chan DA, Sutphin PD, Nguyen P, Turcotte S, Lai EL, Wu J, Solow-Cordero DE, Bouley DM, Graves EE, Denny WA, Hay MP, Giaccia AJ. Targeting Glut1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality. Sci. Transl. Medicine 3(94):94ra70, 2011 IF: 16.71

Turcotte S and Giaccia AJ. Targeting cancer cells through autophagy for anticancer therapy. Curr Opin in Cell Biol. January 5, 2010 IF:  10.01

Hay MP, Turcotte S, Flanagan JU, Bonnet M, Chan DA, Sutphin PD, Nguyen P, Giaccia AJ and Denny WA. 4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death. J. Med. Chem. . IF:6.05

Turcotte S, Sutphin PD and Giaccia AJ. Targeted therapy for the loss of von Hippel-Lindau in Renal Cell Carcinoma: A novel molecule that induces autophagic cell death. Autophagy 4(7), 2008. IF:11.09

Turcotte S, Chan DA, Sutphin PD, Hay MP, Denny WA and Giaccia AJ. A molecule targeting VHL-deficient Renal Cell Carcinoma that induces autophagy. Cancer Cell 14(1):90-102, 2008 IF:23.9